BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dranoff JA, Wells RG. Portal fibroblasts: Underappreciated mediators of biliary fibrosis. Hepatology 2010;51:1438-44. [PMID: 20209607 DOI: 10.1002/hep.23405] [Cited by in Crossref: 173] [Cited by in F6Publishing: 162] [Article Influence: 14.4] [Reference Citation Analysis]
Number Citing Articles
1 Katsounas A, Trippler M, Wang B, Polis M, Lempicki RA, Kottilil S, Gerken G, Schlaak JF. CCL5 mRNA is a marker for early fibrosis in chronic hepatitis C and is regulated by interferon-α therapy and toll-like receptor 3 signalling: CCL5 and liver fibrosis in chronic hepatitis C. Journal of Viral Hepatitis 2012;19:128-37. [DOI: 10.1111/j.1365-2893.2011.01503.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
2 Yazdani S, Bansal R, Prakash J. Drug targeting to myofibroblasts: Implications for fibrosis and cancer. Advanced Drug Delivery Reviews 2017;121:101-16. [DOI: 10.1016/j.addr.2017.07.010] [Cited by in Crossref: 69] [Cited by in F6Publishing: 70] [Article Influence: 13.8] [Reference Citation Analysis]
3 Ebrahimi H, Naderian M, Sohrabpour AA. New Concepts on Pathogenesis and Diagnosis of Liver Fibrosis; A Review Article. Middle East J Dig Dis. 2016;8:166-178. [PMID: 27698966 DOI: 10.15171/mejdd.2016.29] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 4.3] [Reference Citation Analysis]
4 Fausther M, Lavoie EG, Dranoff JA. Contribution of Myofibroblasts of Different Origins to Liver Fibrosis. Curr Pathobiol Rep 2013;1:225-30. [PMID: 23997993 DOI: 10.1007/s40139-013-0020-0] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 4.1] [Reference Citation Analysis]
5 Catteau X, Simon P, Noël JC. Myofibroblastic reaction is a common event in metastatic disease of breast carcinoma: a descriptive study. Diagn Pathol 2014;9:196. [PMID: 25339428 DOI: 10.1186/s13000-014-0196-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
6 Saiman Y, Sugiyama T, Simchoni N, Spirli C, Bansal MB. Biliary Epithelial Cells Are Not the Predominant Source of Hepatic CXCL12. Am J Pathol 2015;185:1859-66. [PMID: 25934614 DOI: 10.1016/j.ajpath.2015.03.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
7 Fabris L, Spirli C, Cadamuro M, Fiorotto R, Strazzabosco M. Emerging concepts in biliary repair and fibrosis. Am J Physiol Gastrointest Liver Physiol 2017;313:G102-16. [PMID: 28526690 DOI: 10.1152/ajpgi.00452.2016] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 8.4] [Reference Citation Analysis]
8 Fabris L, Perugorria MJ, Mertens J, Björkström NK, Cramer T, Lleo A, Solinas A, Sänger H, Lukacs-Kornek V, Moncsek A, Siebenhüner A, Strazzabosco M. The tumour microenvironment and immune milieu of cholangiocarcinoma. Liver Int 2019;39 Suppl 1:63-78. [PMID: 30907492 DOI: 10.1111/liv.14098] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 15.5] [Reference Citation Analysis]
9 Bae M, Park YK, Lee JY. Food components with antifibrotic activity and implications in prevention of liver disease. J Nutr Biochem 2018;55:1-11. [PMID: 29268106 DOI: 10.1016/j.jnutbio.2017.11.003] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 6.4] [Reference Citation Analysis]
10 Sahin H, Trautwein C, Wasmuth HE. Functional role of chemokines in liver disease models. Nat Rev Gastroenterol Hepatol 2010;7:682-90. [DOI: 10.1038/nrgastro.2010.168] [Cited by in Crossref: 53] [Cited by in F6Publishing: 58] [Article Influence: 4.4] [Reference Citation Analysis]
11 Cong M, Iwaisako K, Jiang C, Kisseleva T. Cell signals influencing hepatic fibrosis. Int J Hepatol. 2012;2012:158547. [PMID: 22973518 DOI: 10.1155/2012/158547] [Cited by in Crossref: 39] [Cited by in F6Publishing: 41] [Article Influence: 3.9] [Reference Citation Analysis]
12 Hoffmann C, Djerir NEH, Danckaert A, Fernandes J, Roux P, Charrueau C, Lachagès AM, Charlotte F, Brocheriou I, Clément K, Aron-Wisnewsky J, Foufelle F, Ratziu V, Hainque B, Bonnefont-Rousselot D, Bigey P, Escriou V. Hepatic stellate cell hypertrophy is associated with metabolic liver fibrosis. Sci Rep 2020;10:3850. [PMID: 32123215 DOI: 10.1038/s41598-020-60615-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
13 Fausther M, Dranoff JA. New insights on the pathogenesis of biliary cirrhosis provided by studies in FXR knockout mice. J Hepatol. 2011;55:939-940. [PMID: 21672564 DOI: 10.1016/j.jhep.2011.04.013] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
14 Joshi N, Kopec AK, Ray JL, Cline-Fedewa H, Nawabi A, Schmitt T, Nault R, Zacharewski TR, Rockwell CE, Flick MJ, Luyendyk JP. Fibrin deposition following bile duct injury limits fibrosis through an αMβ2-dependent mechanism. Blood 2016;127:2751-62. [PMID: 26921287 DOI: 10.1182/blood-2015-09-670703] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 3.3] [Reference Citation Analysis]
15 Kukolj V, Aleksić-kovačević S, Katić-radivojević S, Knežević D, Jovanović M. The role and immunophenotypic characteristics of myofibroblasts in liver of sheep naturally infected with the lancet liver fluke (Dicrocoelium dendriticum). Veterinary Parasitology 2015;208:181-9. [DOI: 10.1016/j.vetpar.2015.01.022] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
16 Fabris L, Sato K, Alpini G, Strazzabosco M. The Tumor Microenvironment in Cholangiocarcinoma Progression. Hepatology 2021;73 Suppl 1:75-85. [PMID: 32500550 DOI: 10.1002/hep.31410] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
17 Karin D, Koyama Y, Brenner D, Kisseleva T. The characteristics of activated portal fibroblasts/myofibroblasts in liver fibrosis. Differentiation 2016;92:84-92. [PMID: 27591095 DOI: 10.1016/j.diff.2016.07.001] [Cited by in Crossref: 53] [Cited by in F6Publishing: 49] [Article Influence: 8.8] [Reference Citation Analysis]
18 Fausther M, Lecka J, Soliman E, Kauffenstein G, Pelletier J, Sheung N, Dranoff JA, Sévigny J. Coexpression of ecto-5'-nucleotidase/CD73 with specific NTPDases differentially regulates adenosine formation in the rat liver. Am J Physiol Gastrointest Liver Physiol 2012;302:G447-59. [PMID: 22135310 DOI: 10.1152/ajpgi.00165.2011] [Cited by in Crossref: 45] [Cited by in F6Publishing: 45] [Article Influence: 4.1] [Reference Citation Analysis]
19 Gomes RN, Manuel F, Nascimento DS. The bright side of fibroblasts: molecular signature and regenerative cues in major organs. NPJ Regen Med 2021;6:43. [PMID: 34376677 DOI: 10.1038/s41536-021-00153-z] [Reference Citation Analysis]
20 Ricci E, Vanosi G, Lindenmair A, Hennerbichler S, Peterbauer-Scherb A, Wolbank S, Cargnoni A, Signoroni PB, Campagnol M, Gabriel C, Redl H, Parolini O. Anti-fibrotic effects of fresh and cryopreserved human amniotic membrane in a rat liver fibrosis model. Cell Tissue Bank 2013;14:475-88. [PMID: 22926336 DOI: 10.1007/s10561-012-9337-x] [Cited by in Crossref: 59] [Cited by in F6Publishing: 59] [Article Influence: 5.9] [Reference Citation Analysis]
21 Bocca C, Novo E, Miglietta A, Parola M. Angiogenesis and Fibrogenesis in Chronic Liver Diseases. Cell Mol Gastroenterol Hepatol 2015;1:477-88. [PMID: 28210697 DOI: 10.1016/j.jcmgh.2015.06.011] [Cited by in Crossref: 66] [Cited by in F6Publishing: 61] [Article Influence: 9.4] [Reference Citation Analysis]
22 Lua I, James D, Wang J, Wang KS, Asahina K. Mesodermal mesenchymal cells give rise to myofibroblasts, but not epithelial cells, in mouse liver injury. Hepatology 2014;60:311-22. [PMID: 24488807 DOI: 10.1002/hep.27035] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 4.8] [Reference Citation Analysis]
23 Ren S, Duffield JS. Pericytes in kidney fibrosis. Curr Opin Nephrol Hypertens 2013;22:471-80. [PMID: 23722183 DOI: 10.1097/MNH.0b013e328362485e] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 3.4] [Reference Citation Analysis]
24 Li Y, Wang J, Asahina K. Mesothelial cells give rise to hepatic stellate cells and myofibroblasts via mesothelial-mesenchymal transition in liver injury. Proc Natl Acad Sci USA. 2013;110:2324-2329. [PMID: 23345421 DOI: 10.1073/pnas.1214136110] [Cited by in Crossref: 129] [Cited by in F6Publishing: 113] [Article Influence: 14.3] [Reference Citation Analysis]
25 Fabris L, Strazzabosco M. Epithelial-mesenchymal interactions in biliary diseases. Semin Liver Dis 2011;31:11-32. [PMID: 21344348 DOI: 10.1055/s-0031-1272832] [Cited by in Crossref: 62] [Cited by in F6Publishing: 55] [Article Influence: 5.6] [Reference Citation Analysis]
26 Fausther M, Dranoff JA. Beyond scar formation: portal myofibroblast-mediated angiogenesis in the fibrotic liver. Hepatology 2015;61:766-8. [PMID: 25502320 DOI: 10.1002/hep.27653] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
27 Wu H, Chen C, Ziani S, Nelson LJ, Ávila MA, Nevzorova YA, Cubero FJ. Fibrotic Events in the Progression of Cholestatic Liver Disease. Cells 2021;10:1107. [PMID: 34062960 DOI: 10.3390/cells10051107] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
28 Hintermann E, Bayer M, Conti CB, Fuchs S, Fausther M, Leung PS, Aurrand-Lions M, Taubert R, Pfeilschifter JM, Friedrich-Rust M, Schuppan D, Dranoff JA, Gershwin ME, Manns MP, Imhof BA, Christen U. Junctional adhesion molecules JAM-B and JAM-C promote autoimmune-mediated liver fibrosis in mice. J Autoimmun 2018;91:83-96. [PMID: 29753567 DOI: 10.1016/j.jaut.2018.05.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
29 de Oliveira SA, de Freitas Souza BS, Sá Barreto EP, Kaneto CM, Neto HA, Azevedo CM, Guimarães ET, de Freitas LA, Ribeiro-Dos-Santos R, Soares MB. Reduction of galectin-3 expression and liver fibrosis after cell therapy in a mouse model of cirrhosis. Cytotherapy 2012;14:339-49. [PMID: 22149185 DOI: 10.3109/14653249.2011.637668] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
30 Wen J. Congenital hepatic fibrosis in autosomal recessive polycystic kidney disease. Clin Transl Sci 2011;4:460-5. [PMID: 22212229 DOI: 10.1111/j.1752-8062.2011.00306.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
31 Jiang L, Fang P, Weemhoff JL, Apte U, Pritchard MT. Evidence for a "Pathogenic Triumvirate" in Congenital Hepatic Fibrosis in Autosomal Recessive Polycystic Kidney Disease. Biomed Res Int 2016;2016:4918798. [PMID: 27891514 DOI: 10.1155/2016/4918798] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
32 Mederacke I, Hsu CC, Troeger JS, Huebener P, Mu X, Dapito DH, Pradere JP, Schwabe RF. Fate tracing reveals hepatic stellate cells as dominant contributors to liver fibrosis independent of its aetiology. Nat Commun. 2013;4:2823. [PMID: 24264436 DOI: 10.1038/ncomms3823] [Cited by in Crossref: 621] [Cited by in F6Publishing: 606] [Article Influence: 77.6] [Reference Citation Analysis]
33 Villesen IF, Daniels SJ, Leeming DJ, Karsdal MA, Nielsen MJ. Review article: the signalling and functional role of the extracellular matrix in the development of liver fibrosis. Aliment Pharmacol Ther 2020;52:85-97. [PMID: 32419162 DOI: 10.1111/apt.15773] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
34 Jiang X, Karlsen TH. Genetics of primary sclerosing cholangitis and pathophysiological implications. Nat Rev Gastroenterol Hepatol 2017;14:279-95. [DOI: 10.1038/nrgastro.2016.154] [Cited by in Crossref: 46] [Cited by in F6Publishing: 39] [Article Influence: 9.2] [Reference Citation Analysis]
35 Berenguer M, Schuppan D. Progression of liver fibrosis in post-transplant hepatitis C: mechanisms, assessment and treatment. J Hepatol. 2013;58:1028-1041. [PMID: 23262248 DOI: 10.1016/j.jhep.2012.12.014] [Cited by in Crossref: 104] [Cited by in F6Publishing: 88] [Article Influence: 10.4] [Reference Citation Analysis]
36 Liberal R, Grant CR. Cirrhosis and autoimmune liver disease: Current understanding. World J Hepatol 2016; 8(28): 1157-1168 [PMID: 27729952 DOI: 10.4254/wjh.v8.i28.1157] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 4.8] [Reference Citation Analysis]
37 Xu J, Liu X, Koyama Y, Wang P, Lan T, Kim IG, Kim IH, Ma HY, Kisseleva T. The types of hepatic myofibroblasts contributing to liver fibrosis of different etiologies. Front Pharmacol 2014;5:167. [PMID: 25100997 DOI: 10.3389/fphar.2014.00167] [Cited by in Crossref: 52] [Cited by in F6Publishing: 53] [Article Influence: 6.5] [Reference Citation Analysis]
38 Wells RG. Portal Fibroblasts in Biliary Fibrosis. Curr Pathobiol Rep 2014;2:185-90. [PMID: 25599013 DOI: 10.1007/s40139-014-0054-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
39 Friedman A, Hao W. Mathematical modeling of liver fibrosis. Math Biosci Eng 2017;14:143-64. [PMID: 27879125 DOI: 10.3934/mbe.2017010] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
40 Li Q, Li JF, Mao XR. Application of artificial intelligence in liver diseases: From diagnosis to treatment. Artif Intell Gastroenterol 2021; 2(5): 133-140 [DOI: 10.35712/aig.v2.i5.133] [Reference Citation Analysis]
41 Liu Z, Wang J, Guo C, Fan X. microRNA-21 mediates epithelial-mesenchymal transition of human hepatocytes via PTEN/Akt pathway. Biomed Pharmacother. 2015;69:24-28. [PMID: 25661333 DOI: 10.1016/j.biopha.2014.10.028] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
42 Rychik J, Veldtman G, Rand E, Russo P, Rome JJ, Krok K, Goldberg DJ, Cahill AM, Wells RG. The precarious state of the liver after a Fontan operation: summary of a multidisciplinary symposium. Pediatr Cardiol 2012;33:1001-12. [PMID: 22534759 DOI: 10.1007/s00246-012-0315-7] [Cited by in Crossref: 206] [Cited by in F6Publishing: 163] [Article Influence: 20.6] [Reference Citation Analysis]
43 Katsumata LW, Miyajima A, Itoh T. Portal fibroblasts marked by the surface antigen Thy1 contribute to fibrosis in mouse models of cholestatic liver injury. Hepatol Commun 2017;1:198-214. [PMID: 29404454 DOI: 10.1002/hep4.1023] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
44 Pritchard MT, McCracken JM. Identifying Novel Targets for Treatment of Liver Fibrosis: What Can We Learn from Injured Tissues which Heal Without a Scar? Curr Drug Targets 2015;16:1332-46. [PMID: 26302807 DOI: 10.2174/1389450116666150825111439] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
45 Mavila N, James D, Shivakumar P, Nguyen MV, Utley S, Mak K, Wu A, Zhou S, Wang L, Vendyres C, Groff M, Asahina K, Wang KS. Expansion of prominin-1-expressing cells in association with fibrosis of biliary atresia. Hepatology 2014;60:941-53. [PMID: 24798639 DOI: 10.1002/hep.27203] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 4.4] [Reference Citation Analysis]
46 Pellicoro A, Ramachandran P, Iredale JP, Fallowfield JA. Liver fibrosis and repair: immune regulation of wound healing in a solid organ. Nat Rev Immunol. 2014;14:181-194. [PMID: 24566915 DOI: 10.1038/nri3623] [Cited by in Crossref: 652] [Cited by in F6Publishing: 628] [Article Influence: 81.5] [Reference Citation Analysis]
47 Chu AS, Diaz R, Hui JJ, Yanger K, Zong Y, Alpini G, Stanger BZ, Wells RG. Lineage tracing demonstrates no evidence of cholangiocyte epithelial-to-mesenchymal transition in murine models of hepatic fibrosis. Hepatology. 2011;53:1685-1695. [PMID: 21520179 DOI: 10.1002/hep.24206] [Cited by in Crossref: 152] [Cited by in F6Publishing: 147] [Article Influence: 13.8] [Reference Citation Analysis]
48 Torok NJ. Dysregulation of redox pathways in liver fibrosis. Am J Physiol Gastrointest Liver Physiol 2016;311:G667-74. [PMID: 27562057 DOI: 10.1152/ajpgi.00050.2016] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 4.5] [Reference Citation Analysis]
49 Sullivan BP, Weinreb PH, Violette SM, Luyendyk JP. The coagulation system contributes to alphaVbeta6 integrin expression and liver fibrosis induced by cholestasis. Am J Pathol 2010;177:2837-49. [PMID: 21037076 DOI: 10.2353/ajpath.2010.100425] [Cited by in Crossref: 59] [Cited by in F6Publishing: 59] [Article Influence: 4.9] [Reference Citation Analysis]
50 He H, Mennone A, Boyer JL, Cai SY. Combination of retinoic acid and ursodeoxycholic acid attenuates liver injury in bile duct-ligated rats and human hepatic cells. Hepatology. 2011;53:548-557. [PMID: 21274875 DOI: 10.1002/hep.24047] [Cited by in Crossref: 77] [Cited by in F6Publishing: 67] [Article Influence: 6.4] [Reference Citation Analysis]
51 Wen M, Liu Y, Chen R, He P, Wu F, Li R, Lin Y. Geniposide suppresses liver injury in a mouse model of DDC-induced sclerosing cholangitis. Phytother Res 2021;35:3799-811. [PMID: 33763888 DOI: 10.1002/ptr.7086] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
52 Crawford JM, Bioulac-sage P, Hytiroglou P. Structure, Function, and Responses to Injury. Macsween's Pathology of the Liver. Elsevier; 2018. pp. 1-87. [DOI: 10.1016/b978-0-7020-6697-9.00001-7] [Cited by in Crossref: 5] [Article Influence: 1.3] [Reference Citation Analysis]
53 Abhilash PA, Harikrishnan R, Indira M. Ascorbic acid is superior to silymarin in the recovery of ethanol-induced inflammatory reactions in hepatocytes of guinea pigs. J Physiol Biochem. 2013;69:785-798. [PMID: 23653339 DOI: 10.1007/s13105-013-0255-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
54 Katsounas A, Schlaak JF, Lempicki RA. CCL5: a double-edged sword in host defense against the hepatitis C virus. Int Rev Immunol 2011;30:366-78. [PMID: 22053974 DOI: 10.3109/08830185.2011.593105] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 2.4] [Reference Citation Analysis]
55 Aseem SO, Huebert RC. Epigenetic Mechanisms of Pancreatobiliary Fibrosis. Curr Treat Options Gastroenterol 2019;17:342-56. [PMID: 31300946 DOI: 10.1007/s11938-019-00239-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
56 Fausther M, Goree JR, Lavoie ÉG, Graham AL, Sévigny J, Dranoff JA. Establishment and characterization of rat portal myofibroblast cell lines. PLoS One 2015;10:e0121161. [PMID: 25822334 DOI: 10.1371/journal.pone.0121161] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
57 SantAnna LB, Hage R, Cardoso MA, Arisawa EA, Cruz MM, Parolini O, Cargnoni A, SantAnna N. Antifibrotic Effects of Human Amniotic Membrane Transplantation in Established Biliary Fibrosis Induced in Rats. Cell Transplant 2016;25:2245-57. [PMID: 27480080 DOI: 10.3727/096368916X692645] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 3.2] [Reference Citation Analysis]
58 Koyama Y, Wang P, Liang S, Iwaisako K, Liu X, Xu J, Zhang M, Sun M, Cong M, Karin D, Taura K, Benner C, Heinz S, Bera T, Brenner DA, Kisseleva T. Mesothelin/mucin 16 signaling in activated portal fibroblasts regulates cholestatic liver fibrosis. J Clin Invest 2017;127:1254-70. [PMID: 28287406 DOI: 10.1172/JCI88845] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21] [Article Influence: 5.8] [Reference Citation Analysis]
59 Lee HS, Choi J, Son T, Wee HJ, Bae SJ, Seo JH, Park JH, Ryu SH, Lee D, Jang MK, Yu E, Chung YH, Kim KW. Altered AKAP12 expression in portal fibroblasts and liver sinusoids mediates transition from hepatic fibrogenesis to fibrosis resolution. Exp Mol Med 2018;50:1-13. [PMID: 29700280 DOI: 10.1038/s12276-018-0074-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
60 Novo E, Cannito S, Paternostro C, Bocca C, Miglietta A, Parola M. Cellular and molecular mechanisms in liver fibrogenesis. Arch Biochem Biophys. 2014;548:20-37. [PMID: 24631571 DOI: 10.1016/j.abb.2014.02.015] [Cited by in Crossref: 121] [Cited by in F6Publishing: 113] [Article Influence: 15.1] [Reference Citation Analysis]
61 Wen JW, Olsen AL, Perepelyuk M, Wells RG. Isolation of rat portal fibroblasts by in situ liver perfusion. J Vis Exp. 2012;3669. [PMID: 22781701 DOI: 10.3791/3669] [Cited by in Crossref: 6] [Cited by in F6Publishing: 13] [Article Influence: 0.6] [Reference Citation Analysis]
62 Guicciardi ME, Gores GJ. Apoptosis as a mechanism for liver disease progression. Semin Liver Dis. 2010;30:402-410. [PMID: 20960379 DOI: 10.1055/s-0030-1267540] [Cited by in Crossref: 105] [Cited by in F6Publishing: 108] [Article Influence: 8.8] [Reference Citation Analysis]
63 Cohen-Naftaly M, Friedman SL. Current status of novel antifibrotic therapies in patients with chronic liver disease. Therap Adv Gastroenterol. 2011;4:391-417. [PMID: 22043231 DOI: 10.1177/1756283x11413002] [Cited by in Crossref: 141] [Cited by in F6Publishing: 71] [Article Influence: 12.8] [Reference Citation Analysis]
64 Demetris AJ, Bellamy CO, Gandhi CR, Prost S, Nakanuma Y, Stolz DB. Functional Immune Anatomy of the Liver-As an Allograft. Am J Transplant. 2016;16:1653-1680. [PMID: 26848550 DOI: 10.1111/ajt.13749] [Cited by in Crossref: 50] [Cited by in F6Publishing: 37] [Article Influence: 8.3] [Reference Citation Analysis]
65 Chen J, Hu Y, Chen L, Liu W, Mu Y, Liu P. The effect and mechanisms of Fuzheng Huayu formula against chronic liver diseases. Biomed Pharmacother 2019;114:108846. [PMID: 30965233 DOI: 10.1016/j.biopha.2019.108846] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
66 Anthony BJ, Ramm GA, McManus DP. Role of resident liver cells in the pathogenesis of schistosomiasis. Trends Parasitol 2012;28:572-9. [PMID: 23099112 DOI: 10.1016/j.pt.2012.09.005] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 3.8] [Reference Citation Analysis]
67 Fingas CD, Bronk SF, Werneburg NW, Mott JL, Guicciardi ME, Cazanave SC, Mertens JC, Sirica AE, Gores GJ. Myofibroblast-derived PDGF-BB promotes Hedgehog survival signaling in cholangiocarcinoma cells. Hepatology. 2011;54:2076-2088. [PMID: 22038837 DOI: 10.1002/hep.24588] [Cited by in Crossref: 102] [Cited by in F6Publishing: 144] [Article Influence: 10.2] [Reference Citation Analysis]
68 Chen YH, Lan T, Li J, Qiu CH, Wu T, Gou HJ, Lu MQ. Gardenia jasminoides attenuates hepatocellular injury and fibrosis in bile duct-ligated rats and human hepatic stellate cells. World J Gastroenterol 2012; 18(48): 7158-7165 [PMID: 23326120 DOI: 10.3748/wjg.v18.i48.7158] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
69 Asahina K, Zhou B, Pu WT, Tsukamoto H. Septum transversum-derived mesothelium gives rise to hepatic stellate cells and perivascular mesenchymal cells in developing mouse liver. Hepatology. 2011;53:983-995. [PMID: 21294146 DOI: 10.1002/hep.24119] [Cited by in Crossref: 198] [Cited by in F6Publishing: 188] [Article Influence: 18.0] [Reference Citation Analysis]
70 Xu J, Kisseleva T. Bone marrow-derived fibrocytes contribute to liver fibrosis. Exp Biol Med (Maywood) 2015;240:691-700. [PMID: 25966982 DOI: 10.1177/1535370215584933] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
71 Zagory JA, Nguyen MV, Wang KS. Recent advances in the pathogenesis and management of biliary atresia. Curr Opin Pediatr 2015;27:389-94. [PMID: 25944310 DOI: 10.1097/MOP.0000000000000214] [Cited by in Crossref: 26] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
72 Chen G, Zhang L, Chen L, Wang H, Zhang Y, Bie P. Role of Integrin αvβ6 in the Pathogenesis of Ischemia-Related Biliary Fibrosis After Liver Transplantation. Transplantation 2013;95:1092-9. [DOI: 10.1097/tp.0b013e3182884866] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
73 Liu T, Xu L, Wang C, Chen K, Xia Y, Li J, Li S, Wu L, Feng J, Xu S, Wang W, Lu X, Fan X, Mo W, Zhou Y, Zhao Y, Guo C. Alleviation of hepatic fibrosis and autophagy via inhibition of transforming growth factor-β1/Smads pathway through shikonin. J Gastroenterol Hepatol 2019;34:263-76. [PMID: 29864192 DOI: 10.1111/jgh.14299] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
74 Sohrabpour AA, Mohamadnejad M, Malekzadeh R. Review article: the reversibility of cirrhosis. Aliment Pharmacol Ther 2012;36:824-32. [PMID: 22966946 DOI: 10.1111/apt.12044] [Cited by in Crossref: 39] [Cited by in F6Publishing: 30] [Article Influence: 4.3] [Reference Citation Analysis]
75 Michelotti GA, Xie G, Swiderska M, Choi SS, Karaca G, Krüger L, Premont R, Yang L, Syn WK, Metzger D, Diehl AM. Smoothened is a master regulator of adult liver repair. J Clin Invest 2013;123:2380-94. [PMID: 23563311 DOI: 10.1172/JCI66904] [Cited by in Crossref: 24] [Cited by in F6Publishing: 99] [Article Influence: 2.7] [Reference Citation Analysis]
76 Nishio T, Koyama Y, Liu X, Rosenthal SB, Yamamoto G, Fuji H, Baglieri J, Li N, Brenner LN, Iwaisako K, Taura K, Hagood JS, LaRusso NF, Bera TK, Pastan I, Brenner DA, Kisseleva T. Immunotherapy-based targeting of MSLN+ activated portal fibroblasts is a strategy for treatment of cholestatic liver fibrosis. Proc Natl Acad Sci U S A 2021;118:e2101270118. [PMID: 34253615 DOI: 10.1073/pnas.2101270118] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
77 Friedman SL. Fibrogenic cell reversion underlies fibrosis regression in liver. Proc Natl Acad Sci USA. 2012;109:9230-9231. [PMID: 22645354 DOI: 10.1073/pnas.1206645109] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 3.6] [Reference Citation Analysis]
78 Puente A, Fortea JI, Cabezas J, Arias Loste MT, Iruzubieta P, Llerena S, Huelin P, Fábrega E, Crespo J. LOXL2-A New Target in Antifibrogenic Therapy? Int J Mol Sci 2019;20:E1634. [PMID: 30986934 DOI: 10.3390/ijms20071634] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 9.3] [Reference Citation Analysis]
79 Rockey DC, Friedman SL. Hepatic Fibrosis and Cirrhosis. Zakim and Boyer's Hepatology. Elsevier; 2012. pp. 64-85. [DOI: 10.1016/b978-1-4377-0881-3.00005-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
80 Parola M, Pinzani M. Liver fibrosis: Pathophysiology, pathogenetic targets and clinical issues. Mol Aspects Med. 2019;65:37-55. [PMID: 30213667 DOI: 10.1016/j.mam.2018.09.002] [Cited by in Crossref: 121] [Cited by in F6Publishing: 127] [Article Influence: 30.3] [Reference Citation Analysis]
81 Fausther M, Sheung N, Saiman Y, Bansal MB, Dranoff JA. Activated hepatic stellate cells upregulate transcription of ecto-5'-nucleotidase/CD73 via specific SP1 and SMAD promoter elements. Am J Physiol Gastrointest Liver Physiol 2012;303:G904-14. [PMID: 22899823 DOI: 10.1152/ajpgi.00015.2012] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 3.9] [Reference Citation Analysis]
82 Dhar D, Baglieri J, Kisseleva T, Brenner DA. Mechanisms of liver fibrosis and its role in liver cancer. Exp Biol Med (Maywood) 2020;245:96-108. [PMID: 31924111 DOI: 10.1177/1535370219898141] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 7.5] [Reference Citation Analysis]
83 Syal G, Fausther M, Dranoff JA. Advances in cholangiocyte immunobiology. Am J Physiol Gastrointest Liver Physiol 2012;303:G1077-86. [PMID: 22961800 DOI: 10.1152/ajpgi.00227.2012] [Cited by in Crossref: 55] [Cited by in F6Publishing: 43] [Article Influence: 5.5] [Reference Citation Analysis]
84 Lemoinne S, Cadoret A, Rautou PE, El Mourabit H, Ratziu V, Corpechot C, Rey C, Bosselut N, Barbu V, Wendum D, Feldmann G, Boulanger C, Henegar C, Housset C, Thabut D. Portal myofibroblasts promote vascular remodeling underlying cirrhosis formation through the release of microparticles. Hepatology. 2015;61:1041-1055. [PMID: 25043701 DOI: 10.1002/hep.27318] [Cited by in Crossref: 76] [Cited by in F6Publishing: 66] [Article Influence: 10.9] [Reference Citation Analysis]
85 Vesterhus M, Karlsen TH. Emerging therapies in primary sclerosing cholangitis: pathophysiological basis and clinical opportunities. J Gastroenterol 2020;55:588-614. [PMID: 32222826 DOI: 10.1007/s00535-020-01681-z] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
86 Locatelli L, Cadamuro M, Spirlì C, Fiorotto R, Lecchi S, Morell CM, Popov Y, Scirpo R, De Matteis M, Amenduni M. Macrophage recruitment by fibrocystin-defective biliary epithelial cells promotes portal fibrosis in congenital hepatic fibrosis. Hepatology. 2016;63:965-982. [PMID: 26645994 DOI: 10.1002/hep.28382] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 7.8] [Reference Citation Analysis]
87 Klingberg F, Hinz B, White ES. The myofibroblast matrix: implications for tissue repair and fibrosis. J Pathol. 2013;229:298-309. [PMID: 22996908 DOI: 10.1002/path.4104] [Cited by in Crossref: 352] [Cited by in F6Publishing: 333] [Article Influence: 39.1] [Reference Citation Analysis]
88 Forbes SJ, Parola M. Liver fibrogenic cells. Best Pract Res Clin Gastroenterol. 2011;25:207-217. [PMID: 21497739 DOI: 10.1016/j.bpg.2011.02.006] [Cited by in Crossref: 69] [Cited by in F6Publishing: 65] [Article Influence: 6.3] [Reference Citation Analysis]
89 Berumen J, Baglieri J, Kisseleva T, Mekeel K. Liver fibrosis: Pathophysiology and clinical implications. Wiley Interdiscip Rev Syst Biol Med. 2020;e1499. [PMID: 32713091 DOI: 10.1002/wsbm.1499] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
90 Chen L, Chen G, Guo Y, Liu L, Xiao L, Fan W, Shi B, Qian Y. Ketanserin, a serotonin 2A receptor antagonist, alleviates ischemia-related biliary fibrosis following donation after cardiac death liver transplantation in rats. Liver Transpl 2014;20:1317-26. [PMID: 25045122 DOI: 10.1002/lt.23947] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
91 Torok NJ, Dranoff JA, Schuppan D, Friedman SL. Strategies and endpoints of antifibrotic drug trials: Summary and recommendations from the AASLD Emerging Trends Conference, Chicago, June 2014. Hepatology. 2015;62:627-634. [PMID: 25626988 DOI: 10.1002/hep.27720] [Cited by in Crossref: 49] [Cited by in F6Publishing: 44] [Article Influence: 7.0] [Reference Citation Analysis]
92 Pinzani M, Luong TV. Pathogenesis of biliary fibrosis. Biochim Biophys Acta Mol Basis Dis. 2018;1864:1279-1283. [PMID: 28754450 DOI: 10.1016/j.bbadis.2017.07.026] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 5.6] [Reference Citation Analysis]
93 Kisseleva T, Brenner D. Molecular and cellular mechanisms of liver fibrosis and its regression. Nat Rev Gastroenterol Hepatol. 2021;18:151-166. [PMID: 33128017 DOI: 10.1038/s41575-020-00372-7] [Cited by in Crossref: 31] [Cited by in F6Publishing: 46] [Article Influence: 15.5] [Reference Citation Analysis]
94 Wang H, Lafdil F, Kong X, Gao B. Signal transducer and activator of transcription 3 in liver diseases: a novel therapeutic target. Int J Biol Sci. 2011;7:536-550. [PMID: 21552420 DOI: 10.7150/ijbs.7.536] [Cited by in Crossref: 164] [Cited by in F6Publishing: 169] [Article Influence: 14.9] [Reference Citation Analysis]
95 Jiang JX, Chen X, Hsu DK, Baghy K, Serizawa N, Scott F, Takada Y, Takada Y, Fukada H, Chen J. Galectin-3 modulates phagocytosis-induced stellate cell activation and liver fibrosis in vivo. Am J Physiol Gastrointest Liver Physiol. 2012;302:G439-G446. [PMID: 22159281 DOI: 10.1152/ajpgi.00257.2011] [Cited by in Crossref: 36] [Cited by in F6Publishing: 40] [Article Influence: 3.3] [Reference Citation Analysis]
96 Crawford JM, Burt AD. Anatomy, pathophysiology and basic mechanisms of disease. MacSween's Pathology of the Liver. Elsevier; 2012. pp. 1-77. [DOI: 10.1016/b978-0-7020-3398-8.00001-5] [Cited by in Crossref: 11] [Article Influence: 1.1] [Reference Citation Analysis]
97 Xu J, Cong M, Park TJ, Scholten D, Brenner DA, Kisseleva T. Contribution of bone marrow-derived fibrocytes to liver fibrosis. Hepatobiliary Surg Nutr 2015;4:34-47. [PMID: 25713803 DOI: 10.3978/j.issn.2304-3881.2015.01.01] [Cited by in F6Publishing: 18] [Reference Citation Analysis]
98 Ortiz C, Schierwagen R, Schaefer L, Klein S, Trepat X, Trebicka J. Extracellular Matrix Remodeling in Chronic Liver Disease. Curr Tissue Microenviron Rep 2021;:1-12. [PMID: 34337431 DOI: 10.1007/s43152-021-00030-3] [Reference Citation Analysis]
99 Chen L, Brenner DA, Kisseleva T. Combatting Fibrosis: Exosome-Based Therapies in the Regression of Liver Fibrosis. Hepatol Commun. 2018;3:180-192. [PMID: 30766956 DOI: 10.1002/hep4.1290] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 7.3] [Reference Citation Analysis]
100 Rizvi S, Mertens JC, Bronk SF, Hirsova P, Dai H, Roberts LR, Kaufmann SH, Gores GJ. Platelet-derived growth factor primes cancer-associated fibroblasts for apoptosis. J Biol Chem 2014;289:22835-49. [PMID: 24973208 DOI: 10.1074/jbc.M114.563064] [Cited by in Crossref: 32] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
101 Penz-Österreicher M, Österreicher CH, Trauner M. Fibrosis in autoimmune and cholestatic liver disease. Best Pract Res Clin Gastroenterol 2011;25:245-58. [PMID: 21497742 DOI: 10.1016/j.bpg.2011.02.001] [Cited by in Crossref: 53] [Cited by in F6Publishing: 44] [Article Influence: 4.8] [Reference Citation Analysis]
102 Rizvi S, Gores GJ. Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology. 2013;145:1215-1229. [PMID: 24140396 DOI: 10.1053/j.gastro.2013.10.013] [Cited by in Crossref: 622] [Cited by in F6Publishing: 626] [Article Influence: 69.1] [Reference Citation Analysis]
103 Puche JE, Saiman Y, Friedman SL. Hepatic stellate cells and liver fibrosis. Compr Physiol. 2013;3:1473-1492. [PMID: 24265236 DOI: 10.1002/cphy.c120035] [Cited by in Crossref: 347] [Cited by in F6Publishing: 346] [Article Influence: 43.4] [Reference Citation Analysis]
104 Sterzer V, Alsamman M, Bretag T, Scholten D. EMT in Liver Fibrosis. Curr Pathobiol Rep 2014;2:201-7. [DOI: 10.1007/s40139-014-0056-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
105 Jiang Y, Xu BH, Rodgers B, Pyrsopoulos N. Characteristics and Inpatient Outcomes of Primary Biliary Cholangitis and Autoimmune Hepatitis Overlap Syndrome. J Clin Transl Hepatol 2021;9:392-8. [PMID: 34221925 DOI: 10.14218/JCTH.2021.00008] [Reference Citation Analysis]
106 Ota N, Hirose H, Kato H, Maeda H, Shiojiri N. Immunohistological analysis on distribution of smooth muscle tissues in livers of various vertebrates with attention to different liver architectures. Ann Anat 2021;233:151594. [PMID: 32911068 DOI: 10.1016/j.aanat.2020.151594] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
107 Meurer SK, Karsdal MA, Weiskirchen R. Advances in the clinical use of collagen as biomarker of liver fibrosis. Expert Rev Mol Diagn 2020;20:947-69. [PMID: 32865433 DOI: 10.1080/14737159.2020.1814746] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
108 Joshi N, Kopec AK, Towery K, Williams KJ, Luyendyk JP. The antifibrinolytic drug tranexamic acid reduces liver injury and fibrosis in a mouse model of chronic bile duct injury. J Pharmacol Exp Ther 2014;349:383-92. [PMID: 24633426 DOI: 10.1124/jpet.113.210880] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
109 Kisseleva T, Brenner DA. Is it the end of the line for the EMT? Hepatology. 2011;53:1433-1435. [PMID: 21433040 DOI: 10.1002/hep.24312] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 1.7] [Reference Citation Analysis]
110 Meurer SK, Tihaa L, Borkham-Kamphorst E, Weiskirchen R. Expression and functional analysis of endoglin in isolated liver cells and its involvement in fibrogenic Smad signalling. Cell Signal. 2011;23:683-699. [PMID: 21146604 DOI: 10.1016/j.cellsig.2010.12.002] [Cited by in Crossref: 46] [Cited by in F6Publishing: 46] [Article Influence: 3.8] [Reference Citation Analysis]
111 Tan G, Pan S, Li J, Dong X, Kang K, Zhao M, Jiang X, Kanwar JR, Qiao H, Jiang H, Sun X. Hydrogen sulfide attenuates carbon tetrachloride-induced hepatotoxicity, liver cirrhosis and portal hypertension in rats. PLoS One 2011;6:e25943. [PMID: 22022478 DOI: 10.1371/journal.pone.0025943] [Cited by in Crossref: 70] [Cited by in F6Publishing: 70] [Article Influence: 6.4] [Reference Citation Analysis]
112 Goree JR, Lavoie EG, Fausther M, Dranoff JA. Expression of mediators of purinergic signaling in human liver cell lines. Purinergic Signal 2014;10:631-8. [PMID: 25194703 DOI: 10.1007/s11302-014-9425-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
113 Iwaisako K, Jiang C, Zhang M, Cong M, Moore-Morris TJ, Park TJ, Liu X, Xu J, Wang P, Paik YH, Meng F, Asagiri M, Murray LA, Hofmann AF, Iida T, Glass CK, Brenner DA, Kisseleva T. Origin of myofibroblasts in the fibrotic liver in mice. Proc Natl Acad Sci USA. 2014;111:E3297-E3305. [PMID: 25074909 DOI: 10.1073/pnas.1400062111] [Cited by in Crossref: 260] [Cited by in F6Publishing: 242] [Article Influence: 32.5] [Reference Citation Analysis]
114 Loeuillard E, El Mourabit H, Lei L, Lemoinne S, Housset C, Cadoret A. Endoplasmic reticulum stress induces inverse regulations of major functions in portal myofibroblasts during liver fibrosis progression. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2018;1864:3688-96. [DOI: 10.1016/j.bbadis.2018.10.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
115 Kawada N. Evolution of hepatic fibrosis research. Hepatol Res. 2011;41:199-208. [PMID: 21338451 DOI: 10.1111/j.1872-034x.2011.00776.x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 23] [Article Influence: 3.6] [Reference Citation Analysis]
116 Perugorria MJ, Murphy LB, Fullard N, Chakraborty JB, Vyrla D, Wilson CL, Oakley F, Mann J, Mann DA. Tumor progression locus 2/Cot is required for activation of extracellular regulated kinase in liver injury and toll-like receptor-induced TIMP-1 gene transcription in hepatic stellate cells in mice. Hepatology 2013;57:1238-49. [PMID: 23080298 DOI: 10.1002/hep.26108] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 3.9] [Reference Citation Analysis]
117 Otranto M, Sarrazy V, Bonté F, Hinz B, Gabbiani G, Desmoulière A. The role of the myofibroblast in tumor stroma remodeling. Cell Adh Migr. 2012;6:203-219. [PMID: 22568985 DOI: 10.4161/cam.20377] [Cited by in Crossref: 142] [Cited by in F6Publishing: 131] [Article Influence: 14.2] [Reference Citation Analysis]
118 Cannito S, Novo E, Parola M. Therapeutic pro-fibrogenic signaling pathways in fibroblasts. Adv Drug Deliv Rev 2017;121:57-84. [PMID: 28578015 DOI: 10.1016/j.addr.2017.05.017] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]
119 Baglieri J, Brenner DA, Kisseleva T. The Role of Fibrosis and Liver-Associated Fibroblasts in the Pathogenesis of Hepatocellular Carcinoma. Int J Mol Sci 2019;20:E1723. [PMID: 30959975 DOI: 10.3390/ijms20071723] [Cited by in Crossref: 59] [Cited by in F6Publishing: 56] [Article Influence: 19.7] [Reference Citation Analysis]
120 Zhou T, Bartelheimer K, Ruping F, Rupp C, Sauer P, Koschny R, Mehrabi A, Mieth M, von Haken R, Weiss KH, Gotthardt DN, Rauber C. Intrahepatic biliary strictures after liver transplantation are morphologically similar to primary sclerosing cholangitis but immunologically distinct. European Journal of Gastroenterology & Hepatology 2020;32:276-84. [DOI: 10.1097/meg.0000000000001649] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
121 Li L, Piontek K, Ishida M, Fausther M, Dranoff JA, Fu R, Mezey E, Gould SJ, Fordjour FK, Meltzer SJ, Sirica AE, Selaru FM. Extracellular vesicles carry microRNA-195 to intrahepatic cholangiocarcinoma and improve survival in a rat model. Hepatology. 2017;65:501-514. [PMID: 27474881 DOI: 10.1002/hep.28735] [Cited by in Crossref: 61] [Cited by in F6Publishing: 71] [Article Influence: 10.2] [Reference Citation Analysis]
122 Jiang JX, Török NJ. Liver Injury and the Activation of the Hepatic Myofibroblasts. Curr Pathobiol Rep. 2013;1:215-223. [PMID: 23977452 DOI: 10.1007/s40139-013-0019-6] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 3.6] [Reference Citation Analysis]
123 Gupta V, Gupta I, Park J, Bram Y, Schwartz RE. Hedgehog Signaling Demarcates a Niche of Fibrogenic Peribiliary Mesenchymal Cells. Gastroenterology 2020;159:624-638.e9. [PMID: 32289375 DOI: 10.1053/j.gastro.2020.03.075] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
124 Karpen HE, Karpen SJ. Bile Acid Metabolism During Development. Fetal and Neonatal Physiology. Elsevier; 2017. pp. 913-929.e4. [DOI: 10.1016/b978-0-323-35214-7.00095-0] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
125 Fuji H, Miller G, Nishio T, Koyama Y, Lam K, Zhang V, Loomba R, Brenner D, Kisseleva T. The role of Mesothelin signaling in Portal Fibroblasts in the pathogenesis of cholestatic liver fibrosis. Front Mol Biosci 2021;8:790032. [PMID: 34966784 DOI: 10.3389/fmolb.2021.790032] [Reference Citation Analysis]
126 Sato K, Hall C, Glaser S, Francis H, Meng F, Alpini G. Pathogenesis of Kupffer Cells in Cholestatic Liver Injury. Am J Pathol. 2016;186:2238-2247. [PMID: 27452297 DOI: 10.1016/j.ajpath.2016.06.003] [Cited by in Crossref: 36] [Cited by in F6Publishing: 39] [Article Influence: 6.0] [Reference Citation Analysis]
127 Friedman SL. Hepatic Fibrosis. In: Schiff ER, Maddrey WC, Sorrell MF, editors. Schiff's Diseases of the Liver. Oxford: Wiley-Blackwell; 2011. pp. 295-315. [DOI: 10.1002/9781119950509.ch12] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
128 Nault R, Fader KA, Ammendolia DA, Dornbos P, Potter D, Sharratt B, Kumagai K, Harkema JR, Lunt SY, Matthews J, Zacharewski T. Dose-Dependent Metabolic Reprogramming and Differential Gene Expression in TCDD-Elicited Hepatic Fibrosis. Toxicol Sci 2016;154:253-66. [PMID: 27562557 DOI: 10.1093/toxsci/kfw163] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 5.8] [Reference Citation Analysis]
129 Mao Y, Zhang S, Yu F, Li H, Guo C, Fan X. Ghrelin Attenuates Liver Fibrosis through Regulation of TGF-β1 Expression and Autophagy. Int J Mol Sci. 2015;16:21911-21930. [PMID: 26378522 DOI: 10.3390/ijms160921911] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 5.1] [Reference Citation Analysis]
130 Pillai S, Center SA, McDonough SP, Demarco J, Pintar J, Henderson AK, Cooper J, Bolton T, Sharpe K, Hill S, Benedict AG, Haviland R. Ductal Plate Malformation in the Liver of Boxer Dogs: Clinical and Histological Features. Vet Pathol 2016;53:602-13. [PMID: 26797094 DOI: 10.1177/0300985815610567] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
131 Juntermanns B, Sydor S, Kaiser GM, Jaradat D, Mertens JC, Sotiropoulos GC, Swoboda S, Neuhaus JP, Meng W, Mathé Z, Baba HA, Canbay A, Paul A, Fingas CD. Polo-like kinase 3 is associated with improved overall survival in cholangiocarcinoma. Liver Int 2015;35:2448-57. [PMID: 25818805 DOI: 10.1111/liv.12839] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
132 Brenner DA, Kisseleva T, Scholten D, Paik YH, Iwaisako K, Inokuchi S, Schnabl B, Seki E, De Minicis S, Oesterreicher C. Origin of myofibroblasts in liver fibrosis. Fibrogenesis Tissue Repair. 2012;5:S17. [PMID: 23259769 DOI: 10.1186/1755-1536-5-s1-s17] [Cited by in Crossref: 69] [Cited by in F6Publishing: 49] [Article Influence: 6.9] [Reference Citation Analysis]
133 Lee Y, Friedman SL. Fibrosis in the Liver. Development, Differentiation and Disease of the Para-Alimentary Tract. Elsevier; 2010. pp. 151-200. [DOI: 10.1016/b978-0-12-385233-5.00006-4] [Cited by in Crossref: 22] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
134 Fingas CD, Mertens JC, Razumilava N, Bronk SF, Sirica AE, Gores GJ. Targeting PDGFR-β in Cholangiocarcinoma. Liver Int. 2012;32:400-409. [PMID: 22133064 DOI: 10.1111/j.1478-3231.2011.02687.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 17] [Article Influence: 0.3] [Reference Citation Analysis]
135 Mercer PF, Chambers RC. Coagulation and coagulation signalling in fibrosis. Biochim Biophys Acta 2013;1832:1018-27. [PMID: 23298546 DOI: 10.1016/j.bbadis.2012.12.013] [Cited by in Crossref: 59] [Cited by in F6Publishing: 56] [Article Influence: 6.6] [Reference Citation Analysis]
136 Novo E, Povero D, Busletta C, Paternostro C, di Bonzo LV, Cannito S, Compagnone A, Bandino A, Marra F, Colombatto S. The biphasic nature of hypoxia-induced directional migration of activated human hepatic stellate cells. J Pathol. 2012;226:588-597. [PMID: 21959987 DOI: 10.1002/path.3005] [Cited by in Crossref: 58] [Cited by in F6Publishing: 55] [Article Influence: 5.3] [Reference Citation Analysis]
137 Li B, Yan C, Wu J, Stephane K, Dong X, Zhang Y, Zhang Y, Yu Q, Zheng K. Clonorchis sinensis ESPs enhance the activation of hepatic stellate cells by a cross-talk of TLR4 and TGF-β/Smads signaling pathway. Acta Tropica 2020;205:105307. [DOI: 10.1016/j.actatropica.2019.105307] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
138 Patsenker E, Schneider V, Ledermann M, Saegesser H, Dorn C, Hellerbrand C, Stickel F. Potent antifibrotic activity of mTOR inhibitors sirolimus and everolimus but not of cyclosporine A and tacrolimus in experimental liver fibrosis. J Hepatol. 2011;55:388-398. [PMID: 21168455 DOI: 10.1016/j.jhep.2010.10.044] [Cited by in Crossref: 83] [Cited by in F6Publishing: 85] [Article Influence: 6.9] [Reference Citation Analysis]
139 Sirica AE. The role of cancer-associated myofibroblasts in intrahepatic cholangiocarcinoma. Nat Rev Gastroenterol Hepatol 2012;9:44-54. [DOI: 10.1038/nrgastro.2011.222] [Cited by in Crossref: 95] [Cited by in F6Publishing: 134] [Article Influence: 8.6] [Reference Citation Analysis]
140 Saxena NK, Anania FA. Adipocytokines and hepatic fibrosis. Trends Endocrinol Metab 2015;26:153-61. [PMID: 25656826 DOI: 10.1016/j.tem.2015.01.002] [Cited by in Crossref: 63] [Cited by in F6Publishing: 53] [Article Influence: 9.0] [Reference Citation Analysis]
141 Schuppan D, Kim YO. Evolving therapies for liver fibrosis. J Clin Invest. 2013;123:1887-1901. [PMID: 23635787 DOI: 10.1172/jci66028] [Cited by in Crossref: 393] [Cited by in F6Publishing: 226] [Article Influence: 43.7] [Reference Citation Analysis]
142 Acharya P, Chouhan K, Weiskirchen S, Weiskirchen R. Cellular Mechanisms of Liver Fibrosis. Front Pharmacol 2021;12:671640. [PMID: 34025430 DOI: 10.3389/fphar.2021.671640] [Reference Citation Analysis]
143 Latasa MU, Gil-Puig C, Fernández-Barrena MG, Rodríguez-Ortigosa CM, Banales JM, Urtasun R, Goñi S, Méndez M, Arcelus S, Juanarena N, Recio JA, Lotersztajn S, Prieto J, Berasain C, Corrales FJ, Lecanda J, Avila MA. Oral methylthioadenosine administration attenuates fibrosis and chronic liver disease progression in Mdr2-/- mice. PLoS One 2010;5:e15690. [PMID: 21209952 DOI: 10.1371/journal.pone.0015690] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
144 Elpek G&. Cellular and molecular mechanisms in the pathogenesis of liver fibrosis: An update. World J Gastroenterol 2014; 20(23): 7260-7276 [PMID: 24966597 DOI: 10.3748/wjg.v20.i23.7260] [Cited by in CrossRef: 173] [Cited by in F6Publishing: 156] [Article Influence: 21.6] [Reference Citation Analysis]
145 Shaw TJ, Rognoni E. Dissecting Fibroblast Heterogeneity in Health and Fibrotic Disease. Curr Rheumatol Rep 2020;22:33. [PMID: 32562113 DOI: 10.1007/s11926-020-00903-w] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 11.5] [Reference Citation Analysis]
146 Cui W, Matsuno K, Iwata K, Ibi M, Matsumoto M, Zhang J, Zhu K, Katsuyama M, Torok NJ, Yabe-Nishimura C. NOX1/nicotinamide adenine dinucleotide phosphate, reduced form (NADPH) oxidase promotes proliferation of stellate cells and aggravates liver fibrosis induced by bile duct ligation. Hepatology. 2011;54:949-958. [PMID: 21618578 DOI: 10.1002/hep.24465] [Cited by in Crossref: 78] [Cited by in F6Publishing: 76] [Article Influence: 7.1] [Reference Citation Analysis]
147 Bersini S, Gilardi M, Mora M, Krol S, Arrigoni C, Candrian C, Zanotti S, Moretti M. Tackling muscle fibrosis: From molecular mechanisms to next generation engineered models to predict drug delivery. Advanced Drug Delivery Reviews 2018;129:64-77. [DOI: 10.1016/j.addr.2018.02.009] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
148 Hinz B. Matrix mechanics and regulation of the fibroblast phenotype. Periodontol 2000 2013;63:14-28. [DOI: 10.1111/prd.12030] [Cited by in Crossref: 49] [Cited by in F6Publishing: 44] [Article Influence: 5.4] [Reference Citation Analysis]
149 Zhang DW, Zhao YX, Wei D, Li YL, Zhang Y, Wu J, Xu J, Chen C, Tang H, Zhang W. HAb18G/CD147 promotes activation of hepatic stellate cells and is a target for antibody therapy of liver fibrosis. J Hepatol. 2012;57:1283-1291. [PMID: 22878468 DOI: 10.1016/j.jhep.2012.07.042] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 3.3] [Reference Citation Analysis]
150 Vega-magaña N, Delgado-rizo V, García-benavides L, Toro-arreola SD, Segura-ortega J, Morales ASMZ, Zepeda-nuño JS, Escarra-senmarti M, Gutiérrez-franco J, Haramati J, Bueno-topete MR. Bacterial Translocation Is Linked to Increased Intestinal IFN-γ, IL-4, IL-17, and mucin-2 in Cholestatic Rats. Annals of Hepatology 2018;17:318-29. [DOI: 10.5604/01.3001.0010.8663] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
151 Lu N, Liu Y, Tang A, Chen L, Miao D, Yuan X. Hepatocyte-Specific Ablation of PP2A Catalytic Subunit α Attenuates Liver Fibrosis Progression via TGF-β1/Smad Signaling. Biomed Res Int. 2015;2015:794862. [PMID: 25710025 DOI: 10.1155/2015/794862] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
152 Hinz B, Phan SH, Thannickal VJ, Prunotto M, Desmoulière A, Varga J, De Wever O, Mareel M, Gabbiani G. Recent developments in myofibroblast biology: paradigms for connective tissue remodeling. Am J Pathol. 2012;180:1340-1355. [PMID: 22387320 DOI: 10.1016/j.ajpath.2012.02.004] [Cited by in Crossref: 789] [Cited by in F6Publishing: 765] [Article Influence: 78.9] [Reference Citation Analysis]
153 Ni HM, Williams JA, Yang H, Shi YH, Fan J, Ding WX. Targeting autophagy for the treatment of liver diseases. Pharmacol Res 2012;66:463-74. [PMID: 22871337 DOI: 10.1016/j.phrs.2012.07.003] [Cited by in Crossref: 45] [Cited by in F6Publishing: 47] [Article Influence: 4.5] [Reference Citation Analysis]
154 Wells RG. The portal fibroblast: not just a poor man's stellate cell. Gastroenterology 2014;147:41-7. [PMID: 24814904 DOI: 10.1053/j.gastro.2014.05.001] [Cited by in Crossref: 58] [Cited by in F6Publishing: 51] [Article Influence: 7.3] [Reference Citation Analysis]
155 Yan C, Li B, Fan F, Du Y, Ma R, Cheng XD, Li XY, Zhang B, Yu Q, Wang YG, Tang RX, Zheng KY. The roles of Toll-like receptor 4 in the pathogenesis of pathogen-associated biliary fibrosis caused by Clonorchis sinensis. Sci Rep 2017;7:3909. [PMID: 28634394 DOI: 10.1038/s41598-017-04018-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
156 Sirica AE, Campbell DJ, Dumur CI. Cancer-associated fibroblasts in intrahepatic cholangiocarcinoma. Curr Opin Gastroenterol 2011;27:276-84. [PMID: 21297470 DOI: 10.1097/MOG.0b013e32834405c3] [Cited by in Crossref: 43] [Cited by in F6Publishing: 21] [Article Influence: 3.9] [Reference Citation Analysis]
157 Feldbrügge L, Jiang ZG, Csizmadia E, Mitsuhashi S, Tran S, Yee EU, Rothweiler S, Vaid KA, Sévigny J, Schmelzle M, Popov YV, Robson SC. Distinct roles of ecto-nucleoside triphosphate diphosphohydrolase-2 (NTPDase2) in liver regeneration and fibrosis. Purinergic Signal 2018;14:37-46. [PMID: 29134411 DOI: 10.1007/s11302-017-9590-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
158 Sullivan BP, Cui W, Copple BL, Luyendyk JP. Early growth response factor-1 limits biliary fibrosis in a model of xenobiotic-induced cholestasis in mice. Toxicol Sci 2012;126:267-74. [PMID: 22094456 DOI: 10.1093/toxsci/kfr311] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
159 Zhou YN, Mu YP, Liu P. Sources of myofibroblasts in liver fibrosis. Shijie Huaren Xiaohua Zazhi 2013; 21(31): 3376-3382 [DOI: 10.11569/wcjd.v21.i31.3376] [Reference Citation Analysis]
160 El Taghdouini A, van Grunsven LA. Epigenetic regulation of hepatic stellate cell activation and liver fibrosis. Expert Rev Gastroenterol Hepatol 2016;10:1397-408. [PMID: 27762150 DOI: 10.1080/17474124.2016.1251309] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
161 Zhao YL, Zhu RT, Sun YL. Epithelial-mesenchymal transition in liver fibrosis. Biomed Rep 2016;4:269-74. [PMID: 26998262 DOI: 10.3892/br.2016.578] [Cited by in Crossref: 51] [Cited by in F6Publishing: 52] [Article Influence: 8.5] [Reference Citation Analysis]
162 Onozuka I, Kakinuma S, Kamiya A, Miyoshi M, Sakamoto N, Kiyohashi K, Watanabe T, Funaoka Y, Ueyama M, Nakagawa M, Koshikawa N, Seiki M, Nakauchi H, Watanabe M. Cholestatic liver fibrosis and toxin-induced fibrosis are exacerbated in matrix metalloproteinase-2 deficient mice. Biochem Biophys Res Commun 2011;406:134-40. [PMID: 21300023 DOI: 10.1016/j.bbrc.2011.02.012] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 2.7] [Reference Citation Analysis]
163 Foglia B, Sutti S, Pedicini D, Cannito S, Bocca C, Maggiora M, Bevacqua MR, Rosso C, Bugianesi E, Albano E, Novo E, Parola M. Oncostatin M, A Profibrogenic Mediator Overexpressed in Non-Alcoholic Fatty Liver Disease, Stimulates Migration of Hepatic Myofibroblasts. Cells 2019;9:E28. [PMID: 31861914 DOI: 10.3390/cells9010028] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
164 Rajapaksha IG, Gunarathne LS, Asadi K, Cunningham SC, Sharland A, Alexander IE, Angus PW, Herath CB. Liver-Targeted Angiotensin Converting Enzyme 2 Therapy Inhibits Chronic Biliary Fibrosis in Multiple Drug-Resistant Gene 2-Knockout Mice. Hepatol Commun. 2019;3:1656-1673. [PMID: 31832573 DOI: 10.1002/hep4.1434] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]